MF-438

MF-438 is a potent and selective small molecule inhibitor of stearoyl-CoA desaturase 1 (SCD1), the rate-limiting enzyme responsible for the synthesis of monounsaturated fatty acids (MUFAs) from saturated fatty acids (SFAs). By blocking the conversion of stearic acid to oleic acid and palmitic acid to palmitoleic acid, MF-438 disrupts lipid metabolism and membrane composition. In preclinical research, particularly concerning the link between obesity and oncology, MF-438 has been shown to counteract the protumorigenic effects of the adipokine leptin. It inhibits leptin-induced mitochondrial respiration, ATP production, and oncogenic features such as cell growth and motility in estrogen receptor-positive breast cancer models. While primarily used as a pharmacological tool in research, it represents a class of metabolic inhibitors investigated for their potential to treat obesity-driven cancer progression and other metabolic disorders.